NPM1-ALK-dependent MAPK8,9 phosphorylation

Stable Identifier
R-HSA-9851078
Type
Reaction [omitted]
Species
Homo sapiens
Compartment
cytosol
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
NPM1-ALK-dependent MAPK8,9 phosphorylation
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
NPM1-ALK promotes the phosphorylation of MAPK8 and MAPK9 (also known as JNK1 and2) in a manner that depends on ALK kinase activity. Activation of JNKs in ALCL cells contributes to cellular proliferation by activating members of the AP1 transcription factor family, including c-JUN, that in turn regulate expression of key cell cycle factors such as cyclins and cyclin inhibitors (Leventaki et al, 2007; Cui et al, 2009; reviewed in Shaulian and Karin, 2002)
Literature References
PubMed ID Title Journal Year
17416736 NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma

Leventaki, V, Drakos, E, Medeiros, LJ, Lim, MS, Elenitoba-Johnson, KS, Claret, FX, Rassidakis, GZ

Blood 2007
11988758 AP-1 as a regulator of cell life and death

Shaulian, E, Karin, M

Nat. Cell Biol. 2002
19286999 NPM-ALK inhibits the p53 tumor suppressor pathway in an MDM2 and JNK-dependent manner

Cui, YX, Kerby, A, McDuff, FK, Ye, H, Turner, SD

Blood 2009
Participants
Input
Output
Participates
as an event of
This event is regulated
Positively by
Regulator
NPM1(1-117)-p-7Y ALK(1058-1620) fusion dimer [cytosol] (Homo sapiens)
Disease
Name Identifier Synonyms
anaplastic large cell lymphoma DOID:0050744
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Cross References
Mondo
Authored
Rothfels, K  (2023-10-14)
Reviewed
Turner, S  (2023-11-08)
Created
Rothfels, K  (2023-10-12)
Cite Us!